Articles

Poll

Podcasts

Slideshows

Videos

Hepatology

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

DAA Use Increased After State Medicaid Programs Eased HCV Treatment Restrictions

Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.

Inequities in HCV Care Cascade Engagement Persist, Even After Introduction of DAA Therapy

HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.

HBV Viral Load, Surface Antigen Positivity Not Independently Associated with NAFLD

An analysis of NHANES data found no significant association between HCV infection and risk of prostate cancer, contrary to findings from previous research.

Study Debunks Association Between Hepatitis C, Prostate Cancer

Talal highlights the use of facilitated telemedicine for increasing access to HCV treatment and other areas it might expand access for underserved patient populations.

Facilitated Telemedicine’s Potential for Vulnerable Patient Populations, with Andrew Talal, MD

Results highlight increased safety and efficacy of curative HCV therapy among reproductive-age female patients compared with males, potentially preventing vertical infection transmission.

Safety, Efficacy of DAAs in Reproductive-Age Women Aid Prevention of Vertical HCV Transmission

The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics including treatment eligibility, diagnostics, and service delivery. 

WHO Releases New Hepatitis B Guidelines

Talal discusses the integration of a facilitated telemedicine approach into opioid treatment centers in New York, giving people with opioid use disorder easier access to HCV treatment.

Increasing Access to HCV Treatment Through Facilitated Telemedicine, with Andrew Talal, MD

Participants who received facilitated telemedicine initiated DAA therapy faster and had greater cure rates than those who were referred to an off-site hepatitis specialist.

Facilitated Telemedicine Through Opioid Treatment Program Increases HCV Treatment Access

Our March 2024 hepatology month in review highlights HCPLive’s coverage of the FDA approval of resmetirom for MASH/NASH and other key hepatic pipeline news.

Hepatology Month in Review: March 2024

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.